Human 3 with Brom and Sam

Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.   Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders.  Mindstate participated in Y Combinator in 2021.    Check out Mindstate @ https://www.mindstate.design/

Mental health treatment is often inaccessible, inadequate, and ineffective. However, Nue Life is working to change this through its 360-degree approach to patient health, leveraging ketamine and the integration of tech.   Check out Nue.Life here:  https://nue.life/    ⏰  Timestamps:   0:00 intro and Juan Pablo’s backstory  5:30 how Nue Life got started   11:00 the Nue Life patient experience    20:40 the intersection of data and mental health  32:30 competition in the Ketamine landscape   37:00 is ketamine addictive?   45:00 the future of at-home ketamine and the Ryan Haight act  49:15 legal psilocybin in Oregon?  53:30 what’s next for Nue Life?